96-Well Cell Transformation Assays, Standard Soft Agar

96-Well Cell Transformation Assays, Standard Soft Agar
  • Uses traditional 3D soft agar matrix
  • Fully quantify cell transformation with no manual cell counting
  • Results in 7-8 days, not 3 weeks

 

Frequently Asked Questions about this product

General FAQs about Cell Transformation Assays

Email To BuyerPrint this PageCopy Link
Ordering

Please contact your distributor for pricing.

CytoSelect™ 96-Well Cell Transformation Assay, Soft Agar Colony Formation
Catalog Number
CBA-130
Size
96 assays
Detection
Fluorometric
Manual/Data Sheet Download
SDS Download
Price
$665.00
CytoSelect™ 96-Well Cell Transformation Assay, Soft Agar Colony Formation
Catalog Number
CBA-130-5
Size
5 x 96 assays
Detection
Fluorometric
Manual/Data Sheet Download
SDS Download
Price
$2,850.00
Product Details

Our CytoSelect™ 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader.

Cells incubated using this assay may not be recovered intact. For recovery of intact viable cells, consider our Soft Agar Assay with Cell Recovery.

CytoSelect™ 96-Well Cell Transformation Assay Principle.

Anchorage-Independent Growth of HeLa Cells. HeLa cells were seeded at various concentrations and cultured for 6 days. HeLa cell transformation was determined according to the assay protocol.

Recent Product Citations
  1. Kim, H.W. et al. (2026). RALY promotes Epithelial-mesenchymal transition in Hepatocellular carcinoma by regulating Snail. Biochem Biophys Res Commun. 805:153402. doi: 10.1016/j.bbrc.2026.153402.
  2. Ko, J.Y. et al. (2026). O-GlcNAcylation of XRCC4 controls its stability and confers resistance to DNA double-strand break damage in cancer cells. Cell Death Dis. 17(1):22. doi: 10.1038/s41419-025-08209-4.
  3. Phermthai, T. et al. (2025). Clinical-grade allogeneic amniotic fluid stem cell banking: quality control for therapeutic applications and drug development. Stem Cell Res Ther. 16(1):509. doi: 10.1186/s13287-025-04654-2.
  4. Malvi, P. et al. (2025). PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. Cell Rep Med. 6(9):102356. doi: 10.1016/j.xcrm.2025.102356.
  5. Kim, Y. et al. (2025). O-GlcNAcylation of NONO regulates paraspeckle component assembly and contributes to colon cancer cell proliferation. Cell Death Discov. 11(1):234. doi: 10.1038/s41420-025-02405-z.
  6. Vitillo, L. et al. (2025). Gain of 20q11.21 in human pluripotent stem cells enhances differentiation to retinal pigment epithelium. Stem Cell Res Ther. 16(1):82. doi: 10.1186/s13287-025-04196-7.
  7. He, C. et al. (2024). HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cells. EMBO Rep. doi: 10.1038/s44319-024-00233-3.
  8. Bugide, S. et al. (2024). ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience. 27(5):109800. doi: 10.1016/j.isci.2024.109800.
  9. Yoon, J.H. et al. (2024). Exosomal LINC00853 promotes progression of gastric cancer via the MAP17/PDZK1/AKT signaling pathway. Noncoding RNA Res. 9(3):876-886. doi: 10.1016/j.ncrna.2024.03.011.
  10. Choi, B.Y. et al. (2023). Engineered Mesenchymal Stem Cells Over-Expressing BDNF Protect the Brain from Traumatic Brain Injury-Induced Neuronal Death, Neurological Deficits, and Cognitive Impairments. Pharmaceuticals (Basel). 16(3):436. doi: 10.3390/ph16030436.
  11. Ikeda, J. et al. (2023). Hypoxia inducible factor‐1 activator munc‐18‐interacting protein 3 promotes tumour progression in urothelial carcinoma. Clin Transl Disc. 3:e158. doi: 10.1002/ctd2.158.
  12. Hagen, J.T. et al. (2022). Intrinsic adaptations in OXPHOS power output and reduced tumorigenicity characterize doxorubicin resistant ovarian cancer cells. Biochim Biophys Acta Bioenerg. 1863(8):148915. doi: 10.1016/j.bbabio.2022.148915.
  13. Switzer, C.H. et al. (2022). NOS2 and S-nitrosothiol signaling induces DNA hypomethylation and LINE-1 retrotransposon expression. Proc Natl Acad Sci U S A. 119(21):e2200022119. doi: 10.1073/pnas.2200022119.
  14. Furuya, K. et al. (2022). Machine learning extracts oncogenic-specific γ-H2AX foci formation pattern upon genotoxic stress. Genes Cells. doi: 10.1111/gtc.13005.
  15. Kim, M. et al. (2022). BRAFV600E Mutation Enhances Estrogen-Induced Metastatic Potential of Thyroid Cancer by Regulating the Expression of Estrogen Receptors. Endocrinol Metab (Seoul). 37(6):879-890. doi: 10.3803/EnM.2022.1563.
  16. Toh, P.J.Y. et al. (2022). Optogenetic control of YAP cellular localisation and function. EMBO Rep. doi: 10.15252/embr.202154401.
  17. Lee, A.R. et al. (2022). Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer. Sci Rep. 12(1):2928. doi: 10.1038/s41598-022-06621-w.
  18. Wang, Y. et al. (2022). Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6. J Ovarian Res. 15(1):25. doi: 10.1186/s13048-021-00937-3.
  19. Andriolo, G. et al. (2021). GMP-Grade Methods for Cardiac Progenitor Cells: Cell Bank Production and Quality Control. Methods Mol Biol. doi: 10.1007/7651_2020_286.
  20. Tan, T.T. et al. (2021). Assessment of Tumorigenic Potential in Mesenchymal-Stem/Stromal-Cell-Derived Small Extracellular Vesicles (MSC-sEV). Pharmaceuticals. 14(4):345. doi: 10.3390/ph14040345.
  21. Lo, E.K.K. et al. (2021). Low dose of zearalenone elevated colon cancer cell growth through G protein-coupled estrogenic receptor. Sci Rep. 11(1):7403. doi: 10.1038/s41598-021-86788-w.
  22. Park, S. et al. (2021). Cerebral Cavernous Malformation 1 Determines YAP/TAZ Signaling-Dependent Metastatic Hallmarks of Prostate Cancer Cells. Cancers (Basel). 13(5):1125. doi: 10.3390/cancers13051125.
  23. Huang, S.B. et al. (2021). Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling. Cancer Lett. doi: 10.1016/j.canlet.2021.02.008.
  24. Gao, C. et al. (2020). High intratumoral expression of eIF4A1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer. Acta Biochim Biophys Sin (Shanghai). pii: gmz168. doi: 10.1093/abbs/gmz168.
  25. Eckerdt, F.D. et al. (2020). Combined PI3Kα-mTOR Targeting of Glioma Stem Cells. Sci Rep. 10(1):21873. doi: 10.1038/s41598-020-78788-z.
  26. Byun, H.J. et al. (2020). LUCAT1 Epigenetically Downregulates the Tumor Suppressor Genes CXXC4 and SFRP2 in Gastric Cancer. Yonsei Med J. 61(11):923-934. doi: 10.3349/ymj.2020.61.11.923.
  27. Seo, H.G. et al. (2020). Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion. Cell Death Dis. 11(9):815. doi: 10.1038/s41419-020-02999-5.
  28. Chen, J. et al. (2020). Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm Sin B. doi: 10.1016/j.apsb.2020.07.011.
  29. Inoue, S. et al. (2020). Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncol Lett. 19:1741-1750. doi: 10.3892/ol.2020.11290.
  30. Kawai, S. et al. (2020). Three-dimensional culture models mimic colon cancer heterogeneity induced by different microenvironments. Sci Rep. 10(1):3156. doi: 10.1038/s41598-020-60145-9.